News

Net profit of Gland Pharma rose 96.57% to Rs 366.68 crore in the quarter ended March 2026 as against Rs 186.54 crore during the previous quarter ended March 2025. Sales rose 22.31% to Rs 1742.79 crore in the quarter ended March 2026 as against Rs 1424.91 crore during the previous quarter ended March 2025.For the full year,net profit rose 47.07% to Rs 1027.32 crore in the year ended March 2026 as against Rs 698.53 crore during the previous year ended March 2025. Sales rose 14.50% to Rs 6430.65 crore in the year ended March 2026 as against Rs 5616.50 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1742.791424.91 22 6430.655616.50 15 OPM %29.4424.39 -25.3422.59 - PBDT614.46384.09 60 1912.601440.53 33 PBT505.80288.33 75 1488.931062.66 40 NP366.68186.54 97 1027.32698.53 47 Powered by Capital Market - Live News

Gland Pharma will hold a meeting of the Board of Directors of the Company on 15 May 2026.

Gland Pharma has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC). The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Lumify Ophthalmic Solution, 0.025%, of Bausch & Lomb Inc. This Product is indicated to relieve redness of the eye. Powered by Capital Market - Live News

Gland Pharma announced that Dr. Jitendra Gangwal has been appointed as Vice-President (Research and Development), a Senior Management Personnel of the Company with effect from 18 February 2026.Powered by Capital Market - Live News

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/ mL) Single-Dose Bags. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/ mL) of InfoRLife. This Product is indicated to treat Hypercalcemia of Malignancy and Multiple Myeloma and Bone Metastases of Solid Tumors. According to IQVIA, the product had US sales of approximately USD 6.7 million for the twelve months ending November 2025. Powered by Capital Market - Live News